Merry Christmas!!

Cheese 

Oh Christmas Tree' 

Opening Presents on Christmas Morning 

Backup all the DVD's you received this Holiday Season

If you want to be able to ensure that you will be able to enjoy your cherished DVD collection for years and years to come then you should make backup copies. All you need is a DVD writer and a program to make the backup. An excellent source of reference can be found at Doom9.net

Cell Therapeutics will be a Winner!!

If your looking for a company with great potential you need to consider Cell Therapeutics CTIC
They develop Cancer treatments and have some major therapies in clinical trials with expected positive results within the next 3 months. Very risky but we know there are no rewards without risk. Here is an article from Briefing.com.

CTIC Cell Therapeutics: One to watch, several catalysts ahead (7.71 +0.10)

12/02/04

Source: Briefing.com

Shares of Cell Therapeutics are likely to see some action over the next few months as market participants position themselves ahead of crucial catalysts. Its Xyotax lung cancer drug, conjugated and potentially safer form of paclitaxel, is currently in three different Phase III trials.
Data from these trials is expected to become available early 2005 with analysts generally geared towards positive outcome. CIBC said in a Nov 12 note that while it is difficult to predict the outcome of the STELLAR trials, the firm believes that if the trials fail, CTIC would trade in the $3-$4 range; if successful, the stock could trade up to $25.
Yet, Xyotax is only part of CTIC's story. There is also Pixantrone, currently in a Phase III trial in refractory aggressive non-Hodgkin's lymphoma with data expected in H2:05. WR Hambrecht, which rates CTIC as Buy, noted on Nov 8 that the recent data helps support their view that Pixantrone offers significant upside potential for investors regardless of the outcome on Xyotax.
With two possible blockbusters under its belt and several catalysts in sight, CTIC is worth keeping on the radar.